Business Context and Reporting Period
This Form 8-K Current Report covers events occurring between July 22, 2022, and July 26, 2022, for Kiora Pharmaceuticals, Inc. (KPRX), a Delaware corporation listed on The Nasdaq Capital Market. The filing details the entry into a material definitive agreement for a firm commitment underwritten public offering and the subsequent closing of that offering.
Key Financial Metrics and Capital Structure
The Company completed a public offering resulting in net proceeds of approximately $5.3 million after deducting underwriting discounts, commissions, and estimated offering expenses. The offering consisted of the following securities sold at a public offering price of $0.20 per share (or $1,000 per Preferred Share unit):
- Common Stock: 23,695,697 shares issued and sold (including 3,925,525 shares from the full exercise of the overallotment option).
- Series E Convertible Preferred Stock: 1,280 shares issued, convertible into up to 6,400,000 shares of common stock.
- Class A Warrants: 30,095,697 warrants issued to purchase common stock at $0.20 per share, expiring one year after the initial exercise date.
- Class B Warrants: 30,095,697 warrants issued to purchase common stock at $0.20 per share, expiring five years after the initial exercise date.
The filing does not provide specific data on revenue, operating profit, cash flow, margins, or existing debt levels, as this report focuses on the capital raise event rather than periodic financial performance.
Material Changes and Corporate Actions
On July 22, 2022, the Company entered into an Underwriting Agreement with Ladenburg Thalmann & Co. Inc. The offering closed on July 26, 2022, following the full exercise of the 45-day overallotment option by the underwriter. Additionally, the Company filed a Certificate of Designation for Series E Convertible Preferred Stock, establishing its conversion rights, voting limitations, and liquidation preferences relative to other capital stock.
Outlook, Risks, and Unusual Items
Lock-Up Agreements: The Company and its executive officers and directors entered into lock-up agreements prohibiting the sale or transfer of Company securities for 90 days following the date of the Underwriting Agreement, subject to limited exceptions.
Warrant Exercise Conditions: Warrants are initially exercisable only following stockholder approval of the exercise and a reverse stock split to ensure sufficient shares are available. Beneficial ownership limitations restrict holders from exercising warrants if it would result in ownership exceeding 4.99% (or 9.99% upon election) of outstanding common stock.
Preferred Stock Rights: Series E Preferred Stock generally has no voting rights except for specific matters affecting its rights, such as amendments to the Certificate of Designation or adverse changes to its preferences. It ranks on parity with common stock on an as-converted basis and senior to any future junior stock.
Investor Verification Checklist
- Verify the final net proceeds of $5.3 million against the Company's cash balance in subsequent filings.
- Confirm the status of the required reverse stock split and stockholder approval needed to enable warrant exercise.
- Monitor the 90-day lock-up expiration date for potential selling pressure from insiders.
- Review the dilution impact of the 6,400,000 shares issuable upon conversion of Series E Preferred Stock and the 60,191,394 shares underlying the Class A and Class B Warrants.
- Check for any future filings regarding the use of proceeds to fund clinical trials or operations.